MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

Core Insights - MediciNova, Inc. has been awarded the "Contract Research and Development Innovation Award" at the Fifth Annual BioTech Breakthrough Awards for its innovative work on MN-166 (ibudilast) [1][2][3] Company Overview - MediciNova is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases [4] - The company has a late-stage pipeline that includes 11 clinical programs, with MN-166 being the lead asset currently in Phase 3 trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) [4] - MN-166 is also being evaluated in Phase 2 trials for Long COVID and substance dependence, while MN-001 (tipelukast) is in Phase 2 trials for idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver disease (NAFLD) [4] Product Development - MN-166 is designed to inhibit neuroinflammation and promote neuroprotection, targeting several neurological diseases with limited treatment options, including ALS [2][3] - The ongoing Phase 2/3 COMBAT-ALS trial of MN-166 reflects the company's commitment to addressing unmet medical needs in ALS [3] Industry Recognition - The BioTech Breakthrough Awards program recognizes innovative companies and technologies in the life sciences and biotechnology sectors, highlighting excellence in biopharma, therapeutics, genomics, diagnostics, and research tools [3]